
Sana Biotechnology SANA
$ 2.43
-1.62%
Country |
|
IPO year |
2021 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
253 M |
Market Cap[1] |
$ 615 M |
EBITDA (LTM) |
$ -159 M |
P/E (LTM) |
-4.377358 |
P/S (LTM) |
- |
EPS (LTM) |
-0.53 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Annexon
ANNX
|
$ 4.2 | -0.71 % | $ 651 M | Nasdaq Global Select Market | ||
|
AbbVie
ABBV
|
$ 293.87 | 0.19 % | $ 520 B | NYSE,SPB | ||
|
Alnylam Pharmaceuticals
ALNY
|
$ 151.6 | -3.2 % | $ 19.9 B | Nasdaq Global Select Market,SPB | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
$ 4.63 | 21.05 % | $ 20 M | Nasdaq Capital Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Axon Enterprise
AXON
|
$ 302.6 | -0.19 % | $ 23.6 B | Nasdaq Global Select Market,SPB | ||
|
Theratechnologies
THTX
|
- | - | $ 83.9 M | Nasdaq Capital Market | ||
|
Liquidia Corporation
LQDA
|
$ 51.37 | 7.31 % | $ 4.42 B | Nasdaq Capital Market | ||
|
CRISPR Therapeutics AG
CRSP
|
$ 45.05 | -9.97 % | $ 4.05 B | Nasdaq Global Market,SPB | ||
|
Scholar Rock Holding Corporation
SRRK
|
$ 48.48 | -5.96 % | $ 5.56 B | Nasdaq Global Select Market | ||
|
Geron Corporation
GERN
|
$ 0.96 | -3.71 % | $ 640 M | Nasdaq Global Select Market | ||
|
Bristol-Myers Squibb Company
BMY
|
$ 62.8 | 1.06 % | $ 128 B | NYSE,SPB | ||
|
Titan Pharmaceuticals
TTNP
|
- | -3.76 % | $ 3.47 M | Nasdaq Capital Market | ||
|
Kazia Therapeutics Limited
KZIA
|
$ 7.4 | -0.13 % | $ 113 M | Nasdaq Global Select Market | ||
|
Celldex Therapeutics
CLDX
|
$ 30.68 | -1.81 % | $ 2.04 B | Nasdaq Global Select Market | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
$ 4.0 | -6.76 % | $ 48.8 M | Nasdaq Capital Market | ||
|
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
$ 317.26 | 0.99 % | $ 6.14 B | Nasdaq Global Select Market,SPB | ||
|
Eli Lilly and Company
LLY
|
$ 1 432.7 | 1.47 % | $ 1.29 T | NYSE,SPB | ||
|
TCR2 Therapeutics
TCRR
|
- | - | $ 58.1 M | Nasdaq Global Select Market,SPB | ||
|
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | Nasdaq Global Select Market | ||
|
TFF Pharmaceuticals
TFFP
|
- | -60.05 % | $ 125 K | Nasdaq Global Select Market | ||
|
Mesoblast Limited
MESO
|
$ 14.0 | -3.06 % | $ 16.9 B | Nasdaq Global Select Market | ||
|
CorMedix
CRMD
|
$ 5.37 | -2.1 % | $ 387 K | Nasdaq Global Market | ||
|
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | ||
|
MannKind Corporation
MNKD
|
$ 4.22 | 0.84 % | $ 1.29 B | Nasdaq Global Market | ||
|
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | Nasdaq Capital Market | ||
|
MediciNova
MNOV
|
$ 1.4 | -4.76 % | $ 68.7 M | Nasdaq Global Market | ||
|
Merck & Co.
MRK
|
$ 147.75 | -0.68 % | $ 370 B | NYSE,SPB | ||
|
Moderna
MRNA
|
$ 250.79 | -6.77 % | $ 97.6 B | Nasdaq Global Select Market,SPB | ||
|
Axcella Health
AXLA
|
- | -16.42 % | $ 249 M | Nasdaq Global Market | ||
|
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | Nasdaq Capital Market | ||
|
Intellia Therapeutics
NTLA
|
$ 11.18 | -7.72 % | $ 1.21 B | Nasdaq Global Market,SPB | ||
|
Novartis AG
NVS
|
$ 163.39 | -0.18 % | $ 317 B | NYSE | ||
|
Omeros Corporation
OMER
|
$ 17.3 | -1.48 % | $ 1.1 B | Nasdaq Global Select Market | ||
|
Oramed Pharmaceuticals
ORMP
|
$ 3.97 | -0.75 % | $ 164 M | Nasdaq Global Select Market | ||
|
Tyme Technologies
TYME
|
- | 8.07 % | $ 54 M | Nasdaq Capital Market | ||
|
Puma Biotechnology
PBYI
|
$ 8.13 | -3.22 % | $ 407 M | Nasdaq Global Select Market | ||
|
PDS Biotechnology Corporation
PDSB
|
$ 1.02 | -5.09 % | $ 47.3 M | Nasdaq Capital Market | ||
|
Cyclerion Therapeutics
CYCN
|
$ 34.99 | 3.77 % | $ 147 M | Nasdaq Global Select Market | ||
|
Pfizer
PFE
|
$ 29.34 | 0.36 % | $ 167 B | NYSE,SPB | ||
|
Завод ДИОД
DIOD
|
- | - | - | MOEX,SPB | ||
|
PainReform Ltd.
PRFX
|
$ 0.78 | -4.24 % | $ 505 K | Nasdaq Capital Market | ||
|
Prothena Corporation plc
PRTA
|
$ 8.56 | -2.51 % | $ 461 M | Nasdaq Global Select Market,SPB | ||
|
Arcus Biosciences
RCUS
|
$ 18.66 | -1.56 % | $ 2 B | NYSE,SPB | ||
|
Orgenesis
ORGS
|
- | -33.86 % | $ 61.2 M | Nasdaq Capital Market | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
$ 14.9 | -1.03 % | $ 12.4 B | NYSE | ||
|
Regeneron Pharmaceuticals
REGN
|
$ 916.16 | -0.41 % | $ 95.8 B | Nasdaq Global Select Market,SPB | ||
|
Replimune Group
REPL
|
$ 23.3 | 4.67 % | $ 2.16 B | Nasdaq Global Select Market | ||
|
Фармсинтез
LIFE
|
- | - | - | MOEX |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.